Oppenheimer & Co. Inc. lessened its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 17.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,140 shares of the biotechnology company’s stock after selling 1,543 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Sarepta Therapeutics were worth $538,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Evolution Wealth Advisors LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $25,000. Trust Co. of Vermont raised its position in shares of Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 170 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $32,000. BSW Wealth Partners purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $52,000. Finally, Quad Cities Investment Group LLC raised its position in shares of Sarepta Therapeutics by 100.0% during the 3rd quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 200 shares during the period. 94.60% of the stock is currently owned by hedge funds and other institutional investors.
In other Sarepta Therapeutics news, Director Richard Barry bought 5,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, September 13th. The stock was acquired at an average cost of $87.49 per share, with a total value of $437,450.00. Following the completion of the acquisition, the director now owns 3,183,756 shares of the company’s stock, valued at $278,546,812.44. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Douglas S. Ingram bought 16,252 shares of Sarepta Therapeutics stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $123.07 per share, with a total value of $2,000,133.64. Following the completion of the acquisition, the chief executive officer now directly owns 424,405 shares of the company’s stock, valued at approximately $52,231,523.35. The disclosure for this purchase can be found here. Insiders bought 35,752 shares of company stock valued at $3,940,114 over the last ninety days. Corporate insiders own 6.60% of the company’s stock.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.35). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. The company had revenue of $99.04 million during the quarter, compared to analysts’ expectations of $98.49 million. During the same period last year, the firm earned ($1.15) earnings per share. Sarepta Therapeutics’s revenue was up 26.2% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics Inc will post -4.94 EPS for the current fiscal year.
Several analysts have recently commented on SRPT shares. BidaskClub raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Piper Jaffray Companies set a $185.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, September 27th. Guggenheim started coverage on shares of Sarepta Therapeutics in a research report on Friday, November 1st. They set a “buy” rating and a $183.00 price target on the stock. Morgan Stanley reduced their price target on shares of Sarepta Therapeutics from $220.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Finally, Evercore ISI reaffirmed a “buy” rating and set a $200.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $187.78.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: What is a growth and income fund?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.